A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

CompletedOBSERVATIONAL

Enrollment

178

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Canagliflozin 300 mg

Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.

Trial Locations (3)

Diacon Hospital, Bangalore

Dr. A. Ramachandran's Diabetes Hospitals, Chennai

Apollo Hospitals, Kolkata